EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Microtubule‐Targeting Drugs Induce Mesenchymal–Epithelial Transition in Hepatic Stellate Cells

Hayato Urushima iD, Tsutomu Matsubara iD, Hideto Yuasa, Atsuko Daikoku, Gu Qiongya, Hikaru Nakai, Chiho Kadono, Kazuo Ikeda

Liver International · 2026

DOI: 10.1111/liv.70780 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, 2026. Verfasst von Hayato Urushima und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomy and Regenerative Biology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan. Hauptthemen laut MEDLINE: Hepatic Stellate Cells, Epithelial-Mesenchymal Transition, Microtubules, Tubulin Modulators. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Liver fibrosis is a progressive pathological condition characterized by excessive extracellular matrix accumulation, primarily driven by activated hepatic stellate cells (HSCs). While molecular‐based strategies have been extensively explored for HSC deactivation, clinically effective therapies remain elusive. Previous studies suggest that epithelial‐like features of quiescent HSCs are lost upon activation, implying that mesenchymal–epithelial transition (MET) may be a potential therapeutic mechanism for reversing HSC activation.

Methods

To identify compounds capable of reprogramming HSCs, we screened a library of 1134 FDA‐approved drugs using human HSCs (HHSteCs). Morphological changes were quantified by the axial ratio, and functional assays included proliferation, immunofluorescence, Western blotting, and qPCR. Mechanistic analyses focused on microtubule integrity, focal adhesion signalling, and YAP/TAZ activity. Antifibrotic effects in vivo were evaluated using a carbon tetrachloride (CCl 4 )‐induced mouse fibrosis model treated with febantel, the prodrug of fenbendazole.

Results

Five compounds, including taxanes and benzimidazoles, induced epithelial‐like morphology and suppressed HSC activation. All shared the ability to disrupt microtubule dynamics. Fenbendazole exerted the strongest effect, reducing mesenchymal markers while restoring E‐cadherin expression. Mechanistically, fenbendazole impaired focal adhesion signalling, attenuated YAP/TAZ activity, and promoted reassembly of adherens junctions, consistent with durable MET‐like reprogramming. In vivo, febantel administration suppressed α‐SMA and collagen1α1 expression and downregulated fibrogenic genes without altering serum markers of hepatocellular injury.

Conclusions

Our findings identify microtubule‐dynamics inhibitors as potent inducers of MET‐like reprogramming in HSCs. Fenbendazole, in particular, promotes HSC inactivation by linking microtubule disruption to focal adhesion and TAZ suppression, while restoring epithelial junction integrity. These insights provide a mechanistic rationale for the antifibrotic potential of microtubule‐targeting compounds and highlight benzimidazoles as promising candidates for translational development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatic Stellate CellsEpithelial-Mesenchymal TransitionMicrotubulesTubulin ModulatorsLiver CirrhosisAntifibrotic AgentsLiver Cirrhosis, ExperimentalAnimalsHumansCarbon TetrachlorideSignal TransductionMiceYAP-Signaling ProteinsCell ProliferationAdaptor Proteins, Signal TransducingMaleTrans-ActivatorsMice, Inbred C57BLFocal AdhesionsBenzimidazolesTranscription FactorsPhosphoproteins

Substanzen

Carbon TetrachlorideTubulin ModulatorsYAP-Signaling ProteinsAdaptor Proteins, Signal TransducingTrans-ActivatorsBenzimidazolesAntifibrotic AgentsTranscription FactorsWwtr1 protein, mousePhosphoproteins

Autor:innen und Institutionen

  • Department of Anatomy and Regenerative Biology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
  • Laboratory Animal Facility, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.

ORCID-Profile: Hayato Urushima, Tsutomu Matsubara

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Urushima, H., Matsubara, T., Yuasa, H., Daikoku, A., Qiongya, G., Nakai, H., Kadono, C., & Ikeda, K. (2026). Microtubule‐Targeting Drugs Induce Mesenchymal–Epithelial Transition in Hepatic Stellate Cells. Liver International. https://doi.org/10.1111/liv.70780

Vancouver

Urushima H, Matsubara T, Yuasa H, Daikoku A, Qiongya G, Nakai H, et al. Microtubule‐Targeting Drugs Induce Mesenchymal–Epithelial Transition in Hepatic Stellate Cells. Liver International. 2026. doi:10.1111/liv.70780

BibTeX
@article{Urushima2026,
  author = {Urushima, Hayato and Matsubara, Tsutomu and Yuasa, Hideto and Daikoku, Atsuko and Qiongya, Gu and Nakai, Hikaru and Kadono, Chiho and Ikeda, Kazuo},
  title = {Microtubule‐Targeting Drugs Induce Mesenchymal–Epithelial Transition in Hepatic Stellate Cells},
  journal = {Liver International},
  year = {2026},
  doi = {10.1111/liv.70780}
}
Kostenlos starten →